Home/Protocols/Retatrutide
Protocol Reference
Human trial data

Retatrutide protocol

Retatrutide (GIP / GLP-1 / glucagon triple agonist). Dosing on this page comes from a published human trial or an approved product label, cited below.

Category
GLP-1 & Metabolic
Common vials
10, 15, 20, 30, 50 mg
Half-life
~6 days
Route in the literature
Subcutaneous, once weekly
Evidence level
Human trial data

How Retatrutide works

Adds glucagon-receptor agonism to the GIP/GLP-1 combination. Glucagon activity is thought to raise energy expenditure directly, which is the proposed reason for the larger phase 2 weight changes.

Retatrutide dosing schedule

From the phase 2 obesity trial. This compound is still investigational — there is no approved label, so the schedule below is a trial design rather than a marketed product.

PhaseAmountFrequencyNotes
Weeks 1–42 mgOnce weeklyStarting step for the higher arms.
Weeks 5–84 mgOnce weeklyMaintenance for the 4 mg arm.
Weeks 9–126 mgOnce weeklyEscalation step.
Weeks 13–168 mgOnce weeklyMaintenance for the 8 mg arm.
Weeks 17–2010 mgOnce weeklyEscalation step.
Week 21 onward12 mgOnce weeklyHighest arm in the phase 2 trial.

Study length: 48 weeks. Separate arms escalated to 1, 4, 8 and 12 mg maintenance.

Source for this schedule: Jastreboff AM et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial", NEJM 2023. This reproduces what was administered in that work. It is reference information about a study, not a recommendation, and the trial population, monitoring and endpoints are part of what made it a protocol.

Reconstitution and measurement

This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for Retatrutide: 10, 15, 20, 30, 50 mg.

Open the Retatrutide calculator → Unit converter

Storage and stability

Dry powder
Cold, dark and dry. Lyophilized peptide is the stable form — keep it that way until you intend to use it.
After reconstitution
Refrigerate at 2–8 °C, protect from light, and plan around a limited window. Do not freeze a reconstituted vial — freeze-thaw damages peptides.
Mixing
Run bacteriostatic water down the inside wall of the vial rather than onto the powder, then swirl. Never shake.
Inspect before use
A clear solution is expected. Cloudiness or particles mean discard, not use.

Full storage guide → · Cloudy solution?

Reported effects

  • Gastrointestinal effects were dose-related and concentrated in escalation.
  • The trial reported dose-dependent heart-rate increases — the finding most specific to the glucagon component.
  • No approved label exists and long-term safety is not established.

Sourcing Retatrutide

Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.

Retatrutide at Summit Research Supply → Grade a COA first

Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.

For laboratory research use only. This page documents what the published literature reports about Retatrutide. It is not a recommendation, not a treatment plan, and not medical advice. Compounds referenced are sold strictly as research chemicals and are not for human or veterinary use. Some supplier links are affiliate links and may earn us a commission. This never affects tier placement or review conclusions.
Summit Research Supply
Summit Research Supply — COA-verified research peptidesThird-party tested · U.S. fulfillment · new researchers save 10%
Shop →